Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Bristol-Myers Squibb is the lead sponsor of 162 current clinical trials in our USA, UK, China, India, Ireland and EU (CTIS) registers. 76 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Nivolumab, KarXT and Deucravacitinib. The most-studied condition is Schizophrenia.

Company profiles on this site (news, sites, medicines, approvals): Bristol Myers Squibb (US) →Bristol Myers Squibb (IE) →

ClinicalTrials.gov trials by status

Recruiting7652%
Not yet open86%
Active, closed6142%

Trials by phase

Phase 34732%
Observational3121%
Phase 12114%
Phase 1/21510%
Phase 21410%
Phase 2/3107%
Phase 475%

Clinical trials sponsored by Bristol-Myers Squibb

145 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Pan Tumor Rollover Study NCT03899155 · Cancer Drugs: Bevacizumab, Cabozantinib, Capecitabine	Phase 2	Recruiting	2019-08	Ireland, UK, USA, China
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) NCT06937229 · Alzheimer Disease, Agitation Drugs: KarX-EC, KarXT	Phase 3	Recruiting	2025-12	UK, USA, India, China
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy NCT07106762 · Urothelial Cancer Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 2/3	Recruiting	2025-09	Ireland, UK, USA, China
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) NCT07100080 · Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Iza-bren	Phase 2/3	Recruiting	2025-11	UK, USA, India, China
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) NCT07291076 · Hepatocellular Carcinoma (HCC) Drugs: Ipilimumab, Pumitamig	Phase 1/2	Recruiting	2026-03	UK, USA, China
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). NCT06646276 · Extensive-Stage Small Cell Lung Cancer Drugs: Atezolizumab, Carboplatin, Etoposide	Phase 3	Recruiting	2025-02	UK, USA, India, China
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764 · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC) Drugs: Carboplatin, Cisplatin, Imzokitug	Phase 2	Recruiting	2026-08	UK, USA, China
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer NCT06067841 · Metastatic Castration-resistant Prostate Cancer	Phase 1	Recruiting	2023-10	USA
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma NCT05372354 · Multiple Myeloma Drugs: BMS-986158, CC-92480, Dexamethasone	Phase 1/2	Recruiting	2022-10	UK, USA
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis NCT05076175 · Colitis, Ulcerative Drug: Ozanimod	Phase 2/3	Recruiting	2022-05	UK, USA
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses NCT07063342 · Healthy Volunteers Drugs: KarX-EC, KarXT, Xanomeline	Phase 1	Recruiting	2025-06	UK
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer NCT07221357 · ClinicalTrials.gov ↗ · Untreated, Unresectable, or Metastatic Colorectal Cancer Drugs: Bevacizumab, Capox, Folfiri	Phase 2/3	Recruiting	2025-12	UK, USA, India, China
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) NCT06929273 · ClinicalTrials.gov ↗ · Bipolar Disorder Type I With Mania Drugs: KarXT, Valproate	Phase 3	Recruiting	2025-07	USA, India, China
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine NCT07140913 · ClinicalTrials.gov ↗ · Mania, Bipolar Disorder Drug: KarXT	Phase 3	Recruiting	2025-10	USA, India, China
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% NCT06561386 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Nivolumab	Phase 3	Recruiting	2024-10	Ireland, UK, USA, India, China
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis NCT07412704 · Arthritis, Rheumatoid	Phase 1/2	Recruiting	2026-09	USA, China
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) NCT07221149 · ClinicalTrials.gov ↗ · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Drugs: Capox, Folfox, Nivolumab	Phase 2/3	Recruiting	2026-03	UK, USA, India, China
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) NCT07361497 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC) Drugs: Durvalumab, Pumitamig	Phase 3	Recruiting	2026-03	Ireland, UK, USA, India, China
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease NCT07011745 · Alzheimer's Disease Drugs: KarX-EC, KarXT	Phase 3	Recruiting	2025-07	UK, USA
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: BMS-986504, Carboplatin, Cetuximab	Phase 2	Recruiting	2026-07	Ireland, USA, China
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) NCT07293351 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma (RCC) Drugs: Cabozantinib, Casdatifan, Ipilimumab	Phase 1/2	Recruiting	2026-03	Ireland, UK, USA, China
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US NCT07557498 · Obstructive Hypertrophic Cardiomyopathy (oHCM) Drug: Mavacamten	Observational	Recruiting	2026-01	UK
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis NCT04772079 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drug: Deucravacitinib	Phase 3	Recruiting	2021-03	UK
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease NCT06976216 · ClinicalTrials.gov ↗ · Alzheimer's Disease Drugs: KarX-EC, KarXT	Phase 3	Recruiting	2025-07	USA, India
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy NCT06357754 · Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma Drugs: Idecabtagene vicleucel, Lisocabtagene maraleucel	Observational	Recruiting	2023-10	USA
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) NCT06951711 · ClinicalTrials.gov ↗ · Bipolar Disorder Type I With Mania or Mania With Mixed Features Drug: KarXT	Phase 3	Recruiting	2025-06	USA, India, China
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) NCT06855771 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drugs: BMS-986504, Izalontamab Brengitecan	Phase 2	Recruiting	2025-09	UK, USA, China
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) NCT06976203 · ClinicalTrials.gov ↗ · Alzheimer's Disease Drugs: KarX-EC, KarXT	Phase 3	Recruiting	2025-07	UK, USA
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) NCT07361510 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC) Drugs: Pembrolizumab, Pumitamig	Phase 3	Recruiting	2026-03	UK, USA, India, China
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas NCT06090539 · ClinicalTrials.gov ↗ · Relapsed/Refractory Non-Hodgkin Lymphoma Drugs: Epcoritamab, Golcadomide, Mosunetuzumab	Phase 1/2	Recruiting	2023-12	UK, USA, China
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868 · ClinicalTrials.gov ↗ · Breast Neoplasms Drugs: Capecitabine, Carboplatin, Gemcitabine	Phase 2/3	Recruiting	2025-09	UK, USA, India, China
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) NCT05489705 · ClinicalTrials.gov ↗ · Obstructive Hypertrophic Cardiomyopathy Drug: Mavacamten	Observational	Recruiting	2022-08	UK, USA
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis NCT07171983 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis	Phase 1	Recruiting	2026-02	India
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease NCT06481306 · ClinicalTrials.gov ↗ · Anemia, Sickle Cell, Healthy Volunteers Drugs: Famotidine, Pantoprazole	Phase 1/2	Recruiting	2024-07	UK, USA
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) NCT07011732 · ClinicalTrials.gov ↗ · Alzheimer Disease Drugs: KarX-EC, KarXT	Phase 3	Recruiting	2025-07	USA, India, China
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer With MTAP Deletion Drugs: BMS-986504, Carboplatin, Cisplatin	Phase 2/3	Recruiting	2026-01	UK, USA, India, China
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer NCT07325136 · ClinicalTrials.gov ↗ · Relapsed/Refractory Small Cell Lung Cancer Drug: Pumitamig	Phase 1/2	Recruiting	2026-02	USA, China
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT NCT07061288 · Schizophrenia Drug: KarXT	Phase 1	Recruiting	2025-09	USA
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. NCT06476808 · High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)	Phase 1	Recruiting	2024-09	USA
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) NCT07116967 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drugs: Deucravacitinib, Ustekinumab	Phase 3	Recruiting	2025-09	UK, USA, China
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants NCT07175285 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)	Observational	Recruiting	2025-10	UK, USA
A Study to Assess Deucravacitinib Safety in Pregnancy NCT07017699 · Psoriasis (PsO) Drug: Deucravacitinib	Observational	Recruiting	2025-03	USA
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications NCT04877288 · ClinicalTrials.gov ↗ · Renal Allograft Recipients Drugs: Cyclosporine A, Mycophenolate Mofetil, Tacrolimus	Phase 3	Recruiting	2021-07	UK, USA
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder NCT06951698 · ClinicalTrials.gov ↗ · Bipolar-I Disorder With Mania or Mania With Mixed Features Drugs: KarXT, Xanomeline	Phase 3	Recruiting	2025-06	USA
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) NCT06947941 · ClinicalTrials.gov ↗ · Alzheimer Disease, Psychosis Drugs: KarX-EC, KarXT	Phase 3	Recruiting	2026-03	UK, USA
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis NCT06408259 · ClinicalTrials.gov ↗ · Multiple Sclerosis, Relapsing-Remitting Drugs: Fingolimod, Ozanimod	Phase 3	Recruiting	2025-04	USA
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors NCT06618287 · ClinicalTrials.gov ↗ · Lung Cancer, Breast Cancer Drugs: Iza-bren, Nivolumab, Osimertinib	Phase 1/2	Recruiting	2025-02	UK, USA
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 NCT06875960 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Drug: Deucravacitinib	Phase 4	Recruiting	2026-02	USA
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis NCT05744466 · ClinicalTrials.gov ↗ · Psoriasis Drugs: Apremilast, Deucravacitinib	Observational	Recruiting	2022-09	USA
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring NCT05170126 · ClinicalTrials.gov ↗ · Multiple Sclerosis	Observational	Recruiting	2022-07	USA
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring NCT05953402 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Observational	Recruiting	2026-04	USA
A Phase 1 Study of Navlimetostat Tablet Formulations NCT07544628 · ClinicalTrials.gov ↗ · Healthy Participants Drug: Navlimetostat	Phase 1	Recruiting	2026-04	USA
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) NCT07195682 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma Drugs: Ipilimumab, Pumitamig	Phase 1	Recruiting	2026-01	USA
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) NCT07288567 · ClinicalTrials.gov ↗ · Schizophrenia Drug: KarXT	Phase 3	Recruiting	2026-01	USA
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos NCT06551129 · ClinicalTrials.gov ↗ · Obstructive Hypertrophic Cardiomyopathy Drug: Mavacamten	Observational	Recruiting	2024-05	USA
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia NCT07732907 · ClinicalTrials.gov ↗ · Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy Drug: Ozanimod	Observational	Recruiting	2026-06	USA
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants NCT07226817 · ClinicalTrials.gov ↗ · Healthy Volunteers Drug: BMS-986435	Phase 1	Recruiting	2025-11	USA
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies NCT07223047 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Drugs: Cetuximab, Gemcitabine, Nab-paclitaxel	Phase 1/2	Recruiting	2025-11	USA
Mavacamten Pregnancy Surveillance Program NCT05939700 · ClinicalTrials.gov ↗ · Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related Drug: Mavacamten	Observational	Recruiting	2023-11	USA
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis NCT06869551 · ClinicalTrials.gov ↗ · Juvenile Psoriatic Arthritis Drug: Deucravacitinib	Phase 3	Recruiting	2025-03	USA, China
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709 · ClinicalTrials.gov ↗ · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer Drugs: Docetaxel, Imzokitug, Nivolumab	Phase 1/2	Recruiting	2021-05	USA
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration NCT07780383 · ClinicalTrials.gov ↗ · Alzheimer's Disease, Healthy Participants Drug: BMS-986446	Phase 1	Recruiting	2026-08	USA
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors NCT06997029 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer Drugs: Fulvestrant, Palbociclib	Phase 1	Recruiting	2025-08	USA
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors NCT07077434 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: BMS-986504	Phase 1	Recruiting	2025-10	China
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion NCT05245500 · ClinicalTrials.gov ↗ · Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors Drug: BMS-986504	Phase 1	Recruiting	2022-06	USA
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU) NCT07101094 · ClinicalTrials.gov ↗ · Schizophrenia	Observational	Recruiting	2025-09	USA
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors NCT06697197 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Bevacizumab, Nivolumab and rHuPH20	Phase 1/2	Recruiting	2025-02	USA
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT06419634 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndrome Drugs: Azacitidine, Venetoclax	Phase 1	Recruiting	2024-05	USA
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors Drugs: Adagrasib, Cetuximab, Nivolumab	Phase 1	Recruiting	2025-03	USA
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants. NCT07283263 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Recruiting	2025-12	USA
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) NCT07379827 · ClinicalTrials.gov ↗ · Schizophrenia Drug: KarXT	Observational	Recruiting	2026-02	USA
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors NCT07160725 · ClinicalTrials.gov ↗ · Solid Tumours Drug: Pumitamig	Phase 1/2	Recruiting	2025-10	USA, China
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis NCT06979453 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drug: Deucravacitinib	Phase 3	Recruiting	2025-12	USA, China
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants NCT07629999 · ClinicalTrials.gov ↗ · Healthy Volunteers Drugs: Dabigatran Etexilate, Famotidine, Rosuvastatin	Phase 1	Recruiting	2026-07	USA
A Study to Evaluate the Effect of KarXT on Urological Safety NCT07221877 · ClinicalTrials.gov ↗ · Schizophrenia Drug: KarXT	Phase 4	Recruiting	2026-01	USA
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China NCT07361289 · ClinicalTrials.gov ↗ · Hypertrophic Cardiomyopathy Drug: Mavacamten	Observational	Recruiting	2026-01	China
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder NCT07285798 · Irritability Associated With Autism Spectrum Disorder Drugs: KarX-EC, KarXT	Phase 3	Not yet open	2026-09	USA, India
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis NCT07441408 · Pulmonary Fibrosis Drug: Admilparant	Phase 3	Not yet open	2026-12	Ireland, UK, USA, India, China
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism NCT07284745 · Irritability Associated With Autism Spectrum Disorder Drugs: KarX-EC, KarXT	Phase 3	Not yet open	2026-09	USA
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Iza-bren	Phase 3	Not yet open	2026-09	USA, India, China
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India NCT07459543 · ClinicalTrials.gov ↗ · Unresectable Melanoma, Metastatic Melanoma Drugs: Nivolumab, Relatlimab	Phase 4	Not yet open	2026-11	India
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function NCT07763418 · Kidney Failure, Chronic Drug: Golcadomide	Phase 1	Not yet open	2026-08	USA
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder NCT07772531 · ClinicalTrials.gov ↗ · Major Depressive Disorder	Phase 2	Not yet open	2026-10	USA
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants NCT07777133 · ClinicalTrials.gov ↗ · Healthy Female Participants Drug: Navlimetostat	Phase 1	Not yet open	2026-09	USA
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) NCT05617677 · Systemic Lupus Erythematosus Drug: Deucravacitinib	Phase 3	Active, closed	2023-01	Ireland, USA, India, China
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment NCT04908189 · Psoriatic Arthritis Drugs: Apremilast, Deucravacitinib	Phase 3	Active, closed	2021-07	UK, USA, China
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis NCT06025578 · Progressive Pulmonary Fibrosis Drug: Admilparant	Phase 3	Active, closed	2023-10	Ireland, UK, USA, India, China
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors NCT06730750 · Advanced Solid Tumors Drug: Bevacizumab	Phase 1/2	Active, closed	2025-02	USA
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy NCT06253221 · Cardiomyopathy, Hypertrophic Drug: Mavacamten	Phase 3	Active, closed	2024-04	Ireland, UK, USA
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome NCT05946941 · Sjögren's Syndrome Drug: Deucravacitinib	Phase 3	Active, closed	2023-09	UK, USA, China
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma NCT05827016 · Multiple Myeloma Drugs: Iberdomide, Lenalidomide	Phase 3	Active, closed	2023-06	UK, USA, India, China
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread NCT04810078 · Clear Cell Renal Cell Carcinoma Drugs: Nivolumab, Nivolumab and rHuPH20, Opdivo	Phase 3	Active, closed	2021-05	Ireland, USA
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India NCT05891249 · Anemia Drug: Luspatercept	Phase 4	Active, closed	2023-06	India
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) NCT06140836 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drugs: Crizotinib, Repotrectinib	Phase 3	Active, closed	2023-12	USA, India, China
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer NCT03873402 · Renal Cell Carcinoma Drugs: Ipilimumab, Nivolumab	Phase 3	Active, closed	2019-06	USA
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis NCT06003426 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis Drug: Admilparant	Phase 3	Active, closed	2023-09	Ireland, UK, USA, India, China
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs NCT04908202 · ClinicalTrials.gov ↗ · Psoriatic Arthritis Drug: Deucravacitinib	Phase 3	Active, closed	2021-07	Ireland, UK, USA, China
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drugs: Carboplatin, Cisplatin, Docetaxel	Phase 3	Active, closed	2019-11	Ireland, UK, USA, China
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) NCT07076121 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma Drugs: Gemcitabine, Nab-paclitaxel, Navlimetostat	Phase 2/3	Active, closed	2025-10	Ireland, UK, USA, India, China
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) NCT05552976 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma Drugs: Carfilzomib, Dexamethasone, Mezigdomide	Phase 3	Active, closed	2023-01	UK, USA, India, China

Showing the 100 most recently updated of 145 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Bristol-Myers Squibb in the EU trials register (CTIS)

17 trials · 2 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Bristol-Myers Squibb as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion 2025-524285-18-00 · CTIS ↗ · Neoplasms Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 2	Ongoing	Ireland + 6 more
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis 2025-522373-10-00 · CTIS ↗ · Respiratory Tract Diseases Drug: Admilparant	Phase 3	Authorised	Ireland + 13 more
[14C]Navlimetostat Mass Balance Study in Healthy Female Participants 2026-527504-24-00 · Neoplasms	Phase 1	Authorised	Netherlands
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC) 2026-527163-15-00 · Neoplasms Drugs: Cabozantinib, Ipilimumab	Phase 1	Authorised	Czechia, Finland
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) 2026-525170-19-00 · Neoplasms Drugs: Carboplatin, Cisplatin, Infliximab	Phase 2	Ongoing	Italy, Spain, Romania + 2 more
Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503) 2025-524905-34-00 · Neoplasms Drugs: Adagrasib, Cetuximab, Dexamethasone	Phase 2	Ongoing	Greece, Hungary, Poland + 8 more
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis 2025-520666-22-00 · Immune System Diseases Drug: Tocilizumab	Phase 1	Ongoing	Poland, Italy, Spain + 1 more
Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors 2025-523067-38-01 · Neoplasms	Phase 1	Authorised	Spain, France, Italy
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder 2025-524062-16-00 · CTIS ↗ · Nervous System Diseases Drugs: KarX-EC, KarXT	Phase 3	Authorised	Romania
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants 2025-524564-38-00 · CTIS ↗ · Behavior and Behavior Mechanisms	Phase 1	Authorised	Belgium
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) 2025-523602-33-00 · CTIS ↗ · Neoplasms Drug: Ipilimumab	Phase 1	Ongoing	Poland, Spain, Germany + 2 more
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies 2025-523547-35-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Spain
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer 2025-523224-45-00 · CTIS ↗ · Neoplasms Drugs: Bevacizumab, Calcium folinate, Capecitabine	Phase 3	Ongoing	Sweden, Czechia, Belgium + 8 more
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy 2025-521908-22-00 · CTIS ↗ · Neoplasms Drugs: Carboplatin, Cisplatin, Iza-bren	Phase 3	Authorised	Poland, Germany, Italy + 7 more
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK) 2023-503766-24-00 · CTIS ↗ · Immune System Diseases Drugs: Deucravacitinib, Ustekinumab	Phase 3	Ongoing	Romania, Bulgaria, Germany + 9 more
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine 2025-521845-26-00 · CTIS ↗ · Mental Disorders Drug: KarXT	Phase 3	Ongoing	Romania, Poland, France + 3 more
CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3) 2024-519994-20-00 · CTIS ↗ · Mental Disorders Drugs: KarX-EC, KarXT	Phase 3	Ongoing	Croatia, Romania, France + 8 more

Drugs in Bristol-Myers Squibb trials

93 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 53 more in the trial list above.

Conditions in Bristol-Myers Squibb trials

117 conditions

Schizophrenia7 Healthy Volunteers5 Advanced Solid Tumors5 Non-small Cell Lung Cancer (NSCLC)4 Multiple Myeloma4 Non-Small Cell Lung Cancer4 Melanoma4 Alzheimer's Disease4 Plaque Psoriasis4 Carcinoma, Non-Small-Cell Lung3 Alzheimer Disease3 Multiple Sclerosis3 Myelodysplastic Syndromes3 Systemic Lupus Erythematosus2 Urothelial Cancer2Cardiomyopathy, Hypertrophic2Psoriatic Arthritis2Obstructive Hypertrophic Cardiomyopathy (oHCM)2Obstructive Hypertrophic Cardiomyopathy2Systemic Lupus Erythematosus (SLE)2 Rheumatoid Arthritis2Irritability Associated With Autism Spectrum Disorder2Renal Cell Carcinoma2 Non-Hodgkin Lymphoma2

By trial register

Register	Trials	Recruiting
Clinical trials in USA	128	70
Clinical trials in UK	55	31
Clinical trials in China	55	30
Clinical trials in India	31	16
Clinical trials in Ireland	16	6
EU register (CTIS)	17	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Schizophrenia

Sponsor	Trials
Shanghai Mental Health Center	8
China Medical University Hospital	7
Central South University	7
Neurocrine Biosciences	6
University of Pittsburgh	3
Vigonvita Life Sciences	3
Luye Pharma Group	3
Tianjin Anding Hospital	3
Vanda Pharmaceuticals	2
Karuna Therapeutics, Inc., a Bristol Myers Squibb company	2

Sponsors with the most current trials registered for this condition.

Questions about Bristol-Myers Squibb trials

How many clinical trials does Bristol-Myers Squibb sponsor?

Bristol-Myers Squibb is the lead sponsor of 145 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, and 17 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Bristol-Myers Squibb trials recruiting?

Yes. 76 of its 145 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Bristol-Myers Squibb testing?

Its current trials name 93 drugs and biologicals as interventions. The most frequent are Nivolumab (25), KarXT (22), Deucravacitinib (16), Carboplatin (15) and Pemetrexed (13). The number in brackets is how many of its trials name each drug.

Does Bristol-Myers Squibb have clinical trials in Ireland?

Yes. 16 trials in our Ireland register (ClinicalTrials.gov), and 2 trials in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Bristol-Myers Squibb clinical trials